Antibacterial activity of a dual peptide targeting the Escherichia coli sliding clamp and the ribosome. Issue 3 (16th July 2020)

• Record Type: Journal Article
• Authors: André, Christophe; Veillard, Florian; Wolff, Philippe; Lobstein, Anne-Marie; Compain, Guillaume; Monsarrat, Clément; Reichhart, Jean-Marc; Noûs, Camille; Burnouf, Dominique Y.; Guichard, Gilles; Wagner, Jérôme E.
• Is Part Of: RSC chemical biology. Volume 1: Issue 3(2020)
• Page Start: 137
• Page End: 147
• Publication Date: 2020-07-16
• Subjects: 572
• DOI: 10.1039/d0cb00060d
• Languages: English
• ISSNs: 2633-0679

Abstract

Abstract : Bifunctional peptides targeting both the translation and the replication machineries have been developed and shown to act as new antimicrobials. Abstract : The bacterial processivity factor, or sliding clamp (SC), is a target of choice for new antibacterial drugs development. We have previously developed peptides that target Escherichia coli SC and block its interaction with DNA polymerases in vitro . Here, one such SC binding peptide was fused to a Proline-rich AntiMicrobial Peptide (PrAMP) to allow its internalization into E. coli cells. Co-immunoprecipitation assays with a N-terminally modified bifunctional peptide that still enters the bacteria but fails to interact with the bacterial ribosome, the major target of PrAMPs, demonstrate that it actually interacts with the bacterial SC. Moreover, when compared to SC non-binding controls, this peptide induces a ten-fold higher antibacterial activity against E. coli, showing that the observed antimicrobial activity is linked to SC binding. Finally, an unmodified bifunctional compound significantly increases the survival of Drosophila melanogaster flies challenged by an E. coli infection. Our study demonstrates the potential of PrAMPs to transport antibiotics into the bacterial cytoplasm and validates the development of drugs targeting the bacterial processivity factor of Gram-negative bacteria as a promising new class of antibiotics.